MEI Pharma (MEIP)
(Delayed Data from NSDQ)
$2.98 USD
-0.16 (-5.10%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $2.90 -0.08 (-2.68%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$2.98 USD
-0.16 (-5.10%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $2.90 -0.08 (-2.68%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth B Momentum C VGM
Zacks News
J&J (JNJ) Beats Q3 Earnings & Sales Estimates Post Spin-Off
by Zacks Equity Research
J&J (JNJ) beats estimates for third-quarter earnings and sales. It raises full-year sales and earnings guidance.
Editas (EDIT) Gets FDA's RMAT Tag for Gene Therapy to Treat SCD
by Zacks Equity Research
The FDA bestows Regenerative Medicine Advanced Therapy designation to Editas' (EDIT) gene editing therapy, EDIT-301, for the treatment of severe sickle cell disease. Shares rise.
AstraZeneca's (AZN) Tagrisso Combo Gets FDA's Priority Review
by Zacks Equity Research
The FDA accepts and grants priority review to AstraZeneca's (AZN) sNDA, seeking approval of Tagrisso combined with chemotherapy as a first-line treatment for EGFR-mutated advanced NSCLC. A decision is due in first-quarter 2024.
Catalyst (CPRX) Seeks to Increase Maximum Daily Dose for Firdapse
by Zacks Equity Research
The FDA accepts Catalyst's (CPRX) sNDA to increase the indicated maximum daily dosage of Firdapse 10 mg from 80mg to 100mg for treating Lambert-Eaton myasthenic syndrome. The decision is due on Jun 4, 2024.
All You Need to Know About MEI Pharma, Inc. (MEIP) Rating Upgrade to Strong Buy
by Zacks Equity Research
MEI Pharma, Inc. (MEIP) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Procaps Group, S.A. (PROC) Q2 Earnings Surpass Estimates
by Zacks Equity Research
Procaps Group, S.A. (PROC) delivered earnings and revenue surprises of 350% and 2.09%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Catalent (CTLT) Q4 Earnings Miss Estimates
by Zacks Equity Research
Catalent (CTLT) delivered earnings and revenue surprises of -10% and 1.67%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Infinity Pharma (INFI) Stock Up on Advancing Cancer Study
by Zacks Equity Research
Infinity Pharma (INFI) provides insights on the phase II MARIO-8 study design. The study will evaluate eganelisib for squamous cell cancer of the head and neck.
MEI Pharma, Inc. (MEIP) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
MEI Pharma, Inc. (MEIP) delivered earnings and revenue surprises of 10.77% and 501.43%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Heron Therapeutics (HRTX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Heron Therapeutics (HRTX) delivered earnings and revenue surprises of -58.82% and 4.65%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Assertio (ASRT) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Assertio (ASRT) delivered earnings and revenue surprises of -153.85% and 12.40%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Theravance Biopharma (TBPH) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Theravance Bio (TBPH) delivered earnings and revenue surprises of 11.11% and 24.64%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
MEI Pharma, Inc. (MEIP) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
MEI Pharma, Inc. (MEIP) delivered earnings and revenue surprises of 150% and 237.82%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
MEI Pharma, Inc. (MEIP) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
MEI Pharma, Inc. (MEIP) delivered earnings and revenue surprises of 0% and 10.46%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
CV Sciences, Inc. (CVSI) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
CV Sciences, Inc. (CVSI) delivered earnings and revenue surprises of 50% and 6.81%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Fusion Pharmaceuticals Inc. (FUSN) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Fusion Pharmaceuticals Inc. (FUSN) delivered earnings and revenue surprises of -5.77% and 66.80%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
MEI Pharma, Inc. (MEIP) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
MEI Pharma, Inc. (MEIP) delivered earnings and revenue surprises of 0% and 55.10%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Impel Pharmaceuticals Inc. (IMPL) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Impel Pharmaceuticals Inc. (IMPL) delivered earnings and revenue surprises of -8.33% and 9.94%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
InMed Pharmaceuticals Inc. (INM) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
InMed Pharmaceuticals Inc. (INM) delivered earnings and revenue surprises of -8.70% and 27.06%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Recursion Pharmaceuticals (RXRX) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Recursion Pharmaceuticals (RXRX) delivered earnings and revenue surprises of -164.71% and 96.51%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Pacira (PCRX) Q1 Earnings Miss Estimates
by Zacks Equity Research
Pacira (PCRX) delivered earnings and revenue surprises of -13.51% and 0.32%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Mei Pharma (MEIP) to Delay Filing With FDA for Lymphoma Drug
by Zacks Equity Research
Mei Pharma's (MEIP) FDA filing plans for zandelisib for lymphoma indication get derailed after the agency requests more clinical studies. The stock plummets in after-market trading post this news.
MEI Pharma, Inc. (MEIP) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
MEI Pharma, Inc. (MEIP) delivered earnings and revenue surprises of 31.58% and 139.26%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Will MEI Pharma, Inc. (MEIP) Report Negative Q2 Earnings? What You Should Know
by Zacks Equity Research
MEI Pharma, Inc. (MEIP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Do Options Traders Know Something About MEI Pharma (MEIP) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to MEI Pharma (MEIP) stock based on the movements in the options market lately.